Royal London Asset Management LTD Vertex Pharmaceuticals Inc Transaction History

Royal London Asset Management LTD

$38.5 Billion
Q2 2024

A detailed history of Royal London Asset Management LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Royal London Asset Management LTD holds 369,750 shares of VRTX stock, worth $171 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

369,750

Previous 416,246 11.17%

Holding current value

$171 Million

Previous $174 Million 0.39%

% of portfolio

0.45%

Previous 0.44%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$392.81 - $485.53 $18.3 Million - $22.6 Million	-46,496 Reduced 11.17%	369,750 $173 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $11.6 Million - $12.7 Million	28,443 Added 7.33%	416,246 $174 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $927,815 - $1.11 Million	-2,705 Reduced 0.69%	387,803 $158 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $26.7 Million - $28.6 Million	79,001 Added 25.36%	390,508 $136 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $17.7 Million - $19.8 Million	56,234 Added 22.03%	311,507 $110 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $46.6 Million - $53.1 Million	164,396 Added 180.9%	255,273 $80.4 Million
Q4 2022 Feb 09, 2023	BUY	$285.76 - $321.48 $1.26 Million - $1.41 Million	4,395 Added 5.08%	90,877 $26.2 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1.08 Million - $1.2 Million	-3,941 Reduced 4.36%	86,482 $25 Million
Q2 2022 Aug 12, 2022	BUY	$234.96 - $292.55 $154,603 - $192,497	658 Added 0.73%	90,423 $25.5 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $659,388 - $777,168	2,978 Added 3.43%	89,765 $23.4 Million
Q4 2021 Oct 18, 2022	SELL	$177.01 - $223.45 $708,925 - $894,917	-4,005 Reduced 4.41%	86,787 $19.1 Million
Q4 2021 Jan 18, 2022	SELL	$177.01 - $223.45 $708,925 - $894,917	-4,005 Reduced 4.41%	86,787 $19.1 Million
Q3 2021 Oct 18, 2022	SELL	$181.39 - $202.99 $637,585 - $713,509	-3,515 Reduced 3.73%	90,792 $16.5 Million
Q3 2021 Nov 02, 2021	SELL	$181.39 - $202.99 $637,585 - $713,509	-3,515 Reduced 3.73%	90,792 $16.5 Million
Q2 2021 Oct 18, 2022	BUY	$187.49 - $221.1 $728,211 - $858,752	3,884 Added 4.3%	94,307 $19 Million
Q2 2021 Jul 14, 2021	SELL	$187.49 - $221.1 $978,510 - $1.15 Million	-5,219 Reduced 5.24%	94,307 $19 Million
Q1 2021 Oct 17, 2022	BUY	$207.02 - $241.31 $1.88 Million - $2.2 Million	9,103 Added 10.07%	99,526 $21.4 Million
Q1 2021 Apr 13, 2021	BUY	$207.02 - $241.31 $651,905 - $759,885	3,149 Added 3.27%	99,526 $21.4 Million
Q4 2020 Jan 29, 2021	SELL	$207.01 - $276.09 $551,888 - $736,055	-2,666 Reduced 2.69%	96,377 $22.8 Million
Q3 2020 Nov 04, 2020	SELL	$255.65 - $303.1 $4,090 - $4,849	-16 Reduced 0.02%	99,043 $26.8 Million
Q2 2020 Jul 31, 2020	SELL	$225.48 - $295.8 $848,932 - $1.11 Million	-3,765 Reduced 3.66%	99,059 $28.3 Million
Q4 2019 Feb 05, 2020	SELL	$166.71 - $223.91 $155,540 - $208,908	-933 Reduced 0.9%	102,824 $22.5 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $848,437 - $954,907	5,104 Added 5.17%	103,757 $17.6 Million
Q2 2019 Jul 31, 2019	SELL	$164.61 - $190.37 $1.01 Million - $1.17 Million	-6,156 Reduced 5.87%	98,653 $18.1 Million
Q1 2019 Apr 30, 2019	SELL	$163.73 - $194.7 $358,896 - $426,782	-2,192 Reduced 2.05%	104,809 $0
Q4 2018 Jan 29, 2019	BUY	$151.91 - $192.21 $648,655 - $820,736	4,270 Added 4.16%	107,001 $17.3 Million
Q3 2018 Nov 08, 2018	SELL	$167.73 - $192.74 $395,507 - $454,480	-2,358 Reduced 2.24%	102,731 $0
Q2 2018 Sep 19, 2018	BUY	$145.72 - $169.96 $15.3 Million - $17.9 Million	105,089 New	105,089 $17.9 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.

Account

Royal London Asset Management LTD Vertex Pharmaceuticals Inc Transaction History